Latest Industry Insights

Hear how the capabilities of mass spectrometry (MS)-based proteomics are proving themselves in drug development and discovery and what this means for those working in oncology.

At AACR 2023, Technology Networks spoke with Dr. Mark Garner, global cancer segment market manager at Agilent Technologies, to learn how the new SureSelect Cancer CGP assay is empowering the cancer research field.

The 10-year anniversary of SWATH DIA signifies a period of immense growth that is only expected to continue to evolve, influencing a wide range of fields. This article explores key milestones for SWATH DIA since its development.

In this interview, Technology Networks spoke to Dr. Cameron Pitt to learn more about KRAS as a target for cancer therapeutics, avoiding known resistance mechanisms and the effectiveness of two novel KRAS inhibitors.

In this opinion piece, Dr. Gen Li discusses how AI and predictive analytics are transforming oncology clinical trials.

To find out more about how proteomics is providing new insights into cancer dynamics and resistance mechanisms, we spoke to Dr. Ofer Sharon, CEO of OncoHost, a precision diagnostics company.

In this interview, Technology Networks spoke to Dr. Stuart Marcus, founder and chief medical officer of SonALAsense, to find out how ALA sonodynamic therapy could be a more effective treatment for diffuse intrinsic pontine glioma and recurrent glioblastoma.

In this opinion piece, Liz Sparrow discusses the real risk of the UK losing its science and technology communities as they face a series of challenges that are threatening their growth.

This article overviews the science behind the potential use of RRx-001as a “radiation buster” with anti-inflammatory and anti-free radical properties to prevent or reduce both GI-ARS and H-ARS.

We speak with Dr. Niall Martin, CEO of Artios Pharma, to learn more about the development of drugs to target the DNA damage response pathway in cancer.